Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Cash & Current Investments: 2010-2025

Historic Cash & Current Investments for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Sep 2025 value amounting to $140.4 million.

  • Ironwood Pharmaceuticals' Cash & Current Investments rose 59.17% to $140.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $430.3 million, marking a year-over-year increase of 5.61%. This contributed to the annual value of $88.6 million for FY2024, which is 3.90% down from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Cash & Current Investments stood at $140.4 million for Q3 2025, which was up 51.22% from $92.9 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' Cash & Current Investments' 5-year high stood at $741.6 million during Q1 2023, with a 5-year trough of $88.2 million in Q3 2024.
  • Over the past 3 years, Ironwood Pharmaceuticals' median Cash & Current Investments value was $108.5 million (recorded in 2025), while the average stood at $169.7 million.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Cash & Current Investments soared by 98.02% in 2021, and later crashed by 85.98% in 2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' Cash & Current Investments (Quarterly) stood at $621.4 million in 2021, then climbed by 5.81% to $657.5 million in 2022, then plummeted by 85.98% to $92.2 million in 2023, then declined by 3.90% to $88.6 million in 2024, then soared by 59.17% to $140.4 million in 2025.
  • Its Cash & Current Investments stands at $140.4 million for Q3 2025, versus $92.9 million for Q2 2025 and $108.5 million for Q1 2025.